Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Northwest Biotherapeutics (NWBO) Equity Average: 2011-2025

Historic Equity Average for Northwest Biotherapeutics (NWBO) over the last 14 years, with Sep 2025 value amounting to -$104.5 million.

  • Northwest Biotherapeutics' Equity Average fell 33.47% to -$104.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$104.5 million, marking a year-over-year decrease of 33.47%. This contributed to the annual value of -$80.1 million for FY2024, which is 17.34% up from last year.
  • As of Q3 2025, Northwest Biotherapeutics' Equity Average stood at -$104.5 million, which was down 4.59% from -$99.9 million recorded in Q2 2025.
  • Northwest Biotherapeutics' Equity Average's 5-year high stood at -$58.5 million during Q2 2023, with a 5-year trough of -$705.8 million in Q4 2023.
  • Over the past 3 years, Northwest Biotherapeutics' median Equity Average value was -$92.0 million (recorded in 2023), while the average stood at -$197.4 million.
  • Per our database at Business Quant, Northwest Biotherapeutics' Equity Average plummeted by 777.26% in 2021 and then skyrocketed by 88.87% in 2024.
  • Northwest Biotherapeutics' Equity Average (Quarterly) stood at -$212.9 million in 2021, then spiked by 44.34% to -$118.5 million in 2022, then crashed by 495.69% to -$705.8 million in 2023, then spiked by 87.63% to -$87.3 million in 2024, then slumped by 33.47% to -$104.5 million in 2025.
  • Its Equity Average was -$104.5 million in Q3 2025, compared to -$99.9 million in Q2 2025 and -$97.0 million in Q1 2025.